1
|
Ohnishi K. Current status of parasitic diseases in Japan and request from a clinician to parasitologists. Parasitol Int 2024; 103:102952. [PMID: 39179199 DOI: 10.1016/j.parint.2024.102952] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2024] [Revised: 08/19/2024] [Accepted: 08/19/2024] [Indexed: 08/26/2024]
Abstract
In Japan, parasitic diseases are rare today, with the exception of amebiasis and anisakidosis. As a result, many Japanese clinicians have limited knowledge of parasitic diseases and do not consider them important. Parasitology departments in the schools of medicine in Japan have tended to be replaced or downsized, and the amount of time spent for the teaching of parasitology to undergraduate students has been shortened. However, even in Japan, patients with parasitic diseases visit clinics or hospitals. Medical students have to learn the diagnosis and basic treatment of parasitic diseases that could cause death or serious sequelae without proper treatment, and those which are relatively frequently encountered in Japan. It is also essential for the students to know the circumstances they should suspect parasitic diseases. There is nothing restricting a parasitologist from responding to questions and requests from clinicians regarding diagnosis and treatment; rather, it is in the best interest of patients with parasitic diseases to do so based on their professional knowledge.
Collapse
Affiliation(s)
- Kenji Ohnishi
- Department of Emergency Medical Science, Faculty of Medical Science, Suzuka University of Medical Science, 3500-3, Minamitamagaki, Suzuka, Mie Prefecture 513-8670, Japan.
| |
Collapse
|
2
|
Periwal N, Arora P, Thakur A, Agrawal L, Goyal Y, Rathore AS, Anand HS, Kaur B, Sood V. Antiprotozoal peptide prediction using machine learning with effective feature selection techniques. Heliyon 2024; 10:e36163. [PMID: 39247292 PMCID: PMC11380031 DOI: 10.1016/j.heliyon.2024.e36163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2023] [Revised: 08/09/2024] [Accepted: 08/11/2024] [Indexed: 09/10/2024] Open
Abstract
Background Protozoal pathogens pose a considerable threat, leading to notable mortality rates and the ongoing challenge of developing resistance to drugs. This situation underscores the urgent need for alternative therapeutic approaches. Antimicrobial peptides stand out as promising candidates for drug development. However, there is a lack of published research focusing on predicting antimicrobial peptides specifically targeting protozoal pathogens. In this study, we introduce a successful machine learning-based framework designed to predict potential antiprotozoal peptides effective against protozoal pathogens. Objective The primary objective of this study is to classify and predict antiprotozoal peptides using diverse negative datasets. Methods A comprehensive literature review was conducted to gather experimentally validated antiprotozoal peptides, forming the positive dataset for our study. To construct a robust machine learning classifier, multiple negative datasets were incorporated, including (i) non-antimicrobial, (ii) antiviral, (iii) antibacterial, (iv) antifungal, and (v) antimicrobial peptides excluding those targeting protozoal pathogens. Various compositional features of the peptides were extracted using the pfeature algorithm. Two feature selection methods, SVC-L1 and mRMR, were employed to identify highly relevant features crucial for distinguishing between the positive and negative datasets. Additionally, five popular classifiers i.e. Decision Tree, Random Forest, Support Vector Machine, Logistic Regression, and XGBoost were used to build efficient decision models. Results XGBoost was the most effective in classifying antiprotozoal peptides from each negative dataset based on the features selected by the mRMR feature selection method. The proposed machine learning framework efficiently differentiate the antiprotozoal peptides from (i) non-antimicrobial (ii) antiviral (iii) antibacterial (iv) antifungal and (v) antimicrobial with accuracy of 97.27 %, 93.64 %, 86.36 %, 90.91 %, and 89.09 % respectively on the validation dataset. Conclusion The models are incorporated in a user-friendly web server (www.soodlab.com/appred) to predict the antiprotozoal activity of given peptides.
Collapse
Affiliation(s)
- Neha Periwal
- Department of Biochemistry, Jamia Hamdard, India
| | - Pooja Arora
- Department of Zoology, Hansraj College, University of Delhi, India
| | | | | | - Yash Goyal
- Department of Computer Science, Hansraj College, University of Delhi, India
| | - Anand S Rathore
- Department of Zoology, Hansraj College, University of Delhi, India
| | | | - Baljeet Kaur
- Department of Computer Science, Hansraj College, University of Delhi, India
| | - Vikas Sood
- Department of Biochemistry, Jamia Hamdard, India
| |
Collapse
|
3
|
Gulsen SH, Tileklioglu E, Bode E, Cimen H, Ertabaklar H, Ulug D, Ertug S, Wenski SL, Touray M, Hazir C, Bilecenoglu DK, Yildiz I, Bode HB, Hazir S. Antiprotozoal activity of different Xenorhabdus and Photorhabdus bacterial secondary metabolites and identification of bioactive compounds using the easyPACId approach. Sci Rep 2022; 12:10779. [PMID: 35750682 PMCID: PMC9232601 DOI: 10.1038/s41598-022-13722-z] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2022] [Accepted: 05/26/2022] [Indexed: 12/20/2022] Open
Abstract
Natural products have been proven to be important starting points for the development of new drugs. Bacteria in the genera Photorhabdus and Xenorhabdus produce antimicrobial compounds as secondary metabolites to compete with other organisms. Our study is the first comprehensive study screening the anti-protozoal activity of supernatants containing secondary metabolites produced by 5 Photorhabdus and 22 Xenorhabdus species against human parasitic protozoa, Acanthamoeba castellanii, Entamoeba histolytica, Trichomonas vaginalis, Leishmania tropica and Trypanosoma cruzi, and the identification of novel bioactive antiprotozoal compounds using the easyPACId approach (easy Promoter Activated Compound Identification) method. Though not in all species, both bacterial genera produce antiprotozoal compounds effective on human pathogenic protozoa. The promoter exchange mutants revealed that antiprotozoal bioactive compounds produced by Xenorhabdus bacteria were fabclavines, xenocoumacins, xenorhabdins and PAX peptides. Among the bacteria assessed, only P. namnaoensis appears to have acquired amoebicidal property which is effective on E. histolytica trophozoites. These discovered antiprotozoal compounds might serve as starting points for the development of alternative and novel pharmaceutical agents against human parasitic protozoa in the future.
Collapse
Affiliation(s)
- Sebnem Hazal Gulsen
- Department of Biology, Faculty of Arts and Science, Aydin Adnan Menderes University, Aydin, Türkiye
| | - Evren Tileklioglu
- Department of Parasitology, Faculty of Medicine, Aydin Adnan Menderes University, Aydin, Türkiye
| | - Edna Bode
- Max-Planck-Institute for Terrestrial Microbiology Department, Natural Products in Organismic Interactions, Karl-von-Frisch-Str. 10, 35043, Marburg, Germany
| | - Harun Cimen
- Department of Biology, Faculty of Arts and Science, Aydin Adnan Menderes University, Aydin, Türkiye
| | - Hatice Ertabaklar
- Department of Parasitology, Faculty of Medicine, Aydin Adnan Menderes University, Aydin, Türkiye
| | - Derya Ulug
- Department of Biology, Faculty of Arts and Science, Aydin Adnan Menderes University, Aydin, Türkiye
| | - Sema Ertug
- Department of Parasitology, Faculty of Medicine, Aydin Adnan Menderes University, Aydin, Türkiye
| | - Sebastian L Wenski
- Max-Planck-Institute for Terrestrial Microbiology Department, Natural Products in Organismic Interactions, Karl-von-Frisch-Str. 10, 35043, Marburg, Germany
| | - Mustapha Touray
- Department of Biology, Faculty of Arts and Science, Aydin Adnan Menderes University, Aydin, Türkiye
| | - Canan Hazir
- Aydin Health Services Vocational School, Aydin Adnan Menderes University, 09100, Aydin, Türkiye
| | | | - Ibrahim Yildiz
- Department of Parasitology, Faculty of Medicine, Aydin Adnan Menderes University, Aydin, Türkiye
| | - Helge B Bode
- Max-Planck-Institute for Terrestrial Microbiology Department, Natural Products in Organismic Interactions, Karl-von-Frisch-Str. 10, 35043, Marburg, Germany. .,Molekulare Biotechnologie, Fachbereich Biowissenschaften, Goethe Universität Frankfurt, Max-von-Laue-Str. 9, 60438, Frankfurt, Germany. .,Senckenberg Gesellschaft für Naturforschung, 60325, Frankfurt, Germany.
| | - Selcuk Hazir
- Department of Biology, Faculty of Arts and Science, Aydin Adnan Menderes University, Aydin, Türkiye.
| |
Collapse
|
4
|
Li L, Qiu Z, Qi Y, Zhao D, Ali I, Sun C, Xu L, Zheng Z, Ma C. AuNPs/NiFe-LDHs-assisted laser desorption/ionization mass spectrometry for efficient analysis of metronidazole and its metabolites in water samples. JOURNAL OF HAZARDOUS MATERIALS 2022; 423:126893. [PMID: 34479085 DOI: 10.1016/j.jhazmat.2021.126893] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/17/2021] [Revised: 07/21/2021] [Accepted: 08/10/2021] [Indexed: 06/13/2023]
Abstract
Gold nanoparticles (AuNPs) have been widely used as laser desorption/ionization mass spectrometry (LDI-MS) nanomaterials for the analysis of low-molecular-weight samples. Nickel/iron-layered double hydroxides (NiFe-LDHs) nanosheets can support the anchoring of AuNPs and enhance the ability of desorption/ionization. Their hybrid nanocomposites are expected to produce synergistic effects to improve the performance of LDI-MS. In this work, a novel AuNPs/NiFe-LDHs nanomaterial was synthesized by self-assembly method and characterized based on TEM, SEM, XPS, UV-vis and FTIR-ATR. AuNPs/NiFe-LDHs assisted LDI-TOF MS exhibited higher peak intensity and lower background noise compared with conventional organic matrices. Furthermore, excellent salt and protein tolerance, good repeatability and quantification were observed when MNZ and its metabolites were detected in the range of 1-50 ng·μL-1 (R2 > 0.98), with LODs and LOQs of 0.5 ng·μL-1 and 1 ng·μL-1, respectively. This nanocomposite could also be used for the analysis of some other small molecules, such as antibiotics, sugars, amino acids and pesticides, demonstrating the potential to detect a variety of environmental chemicals. Taken together, the developed method combined the advantages of two nanomaterials and can provide rapid and accurate analysis of MNZ and its metabolites in water samples, as well as some other small molecules.
Collapse
Affiliation(s)
- Lingyu Li
- Key Laboratory of Food Processing Technology and Quality Control of Shandong Higher Education Institutes, College of Food Science and Engineering, Shandong Agricultural University, 61 Daizong Street, Tai'an 271018, Shandong, PR China; Key Laboratory for Applied Technology of Sophisticated Analytical Instruments of Shandong Province, Shandong Analysis and Test Center, Qilu University of Technology (Shandong Academy of Sciences), Jinan 250014, Shandong, PR China
| | - Zhichang Qiu
- Key Laboratory of Food Processing Technology and Quality Control of Shandong Higher Education Institutes, College of Food Science and Engineering, Shandong Agricultural University, 61 Daizong Street, Tai'an 271018, Shandong, PR China
| | - Yuanfeng Qi
- School of Environmental and Municipal Engineering, Qingdao University of Technology, Qingdao 266033, Shandong, PR China
| | - Dantong Zhao
- Heze Institute for Food and Drug Control, Heze 274000, Shandong, PR China
| | - Iftikhar Ali
- Department of Chemistry, Karakoram International University, Gilgit-Baltistan, Gilgit 15100, Pakistan
| | - Chenglong Sun
- Key Laboratory for Applied Technology of Sophisticated Analytical Instruments of Shandong Province, Shandong Analysis and Test Center, Qilu University of Technology (Shandong Academy of Sciences), Jinan 250014, Shandong, PR China
| | - Longhua Xu
- Key Laboratory of Food Processing Technology and Quality Control of Shandong Higher Education Institutes, College of Food Science and Engineering, Shandong Agricultural University, 61 Daizong Street, Tai'an 271018, Shandong, PR China
| | - Zhenjia Zheng
- Key Laboratory of Food Processing Technology and Quality Control of Shandong Higher Education Institutes, College of Food Science and Engineering, Shandong Agricultural University, 61 Daizong Street, Tai'an 271018, Shandong, PR China.
| | - Chunxia Ma
- Key Laboratory for Applied Technology of Sophisticated Analytical Instruments of Shandong Province, Shandong Analysis and Test Center, Qilu University of Technology (Shandong Academy of Sciences), Jinan 250014, Shandong, PR China; School of Environmental and Municipal Engineering, Qingdao University of Technology, Qingdao 266033, Shandong, PR China.
| |
Collapse
|
5
|
Abstract
BACKGROUND Infection with the protozoan Entamoeba histolytica is common in low- and middle-income countries, and up to 100,000 people with severe disease die every year. Adequate therapy for amoebic colitis is necessary to reduce illness, prevent development of complicated disease and extraintestinal spread, and decrease transmission. OBJECTIVES To evaluate antiamoebic drugs for treating amoebic colitis. SEARCH METHODS We searched the available literature up to 22 March 2018. We searched the Cochrane Infectious Diseases Group Specialised Register, CENTRAL, MEDLINE, Embase, LILACS, mRCT, and conference proceedings. We contacted individual researchers, organizations, and pharmaceutical companies, and we checked reference lists. SELECTION CRITERIA Randomized controlled trials of antiamoebic drugs given alone or in combination, compared with placebo or another antiamoebic drug, for treating adults and children with a diagnosis of amoebic colitis. DATA COLLECTION AND ANALYSIS Two review authors independently assessed the eligibility and methodological quality of trials and extracted and analysed the data. We calculated clinical and parasitological failure rates and rates of relapse and adverse events as risk ratios (RRs) with 95% confidence intervals (CIs), using a random-effects model. We determined statistical heterogeneity and explored possible sources of heterogeneity using subgroup analyses. We carried out sensitivity analysis by using trial quality to assess the robustness of reported results. MAIN RESULTS In total, 41 trials (4999 participants) met the inclusion criteria of this review. In this update, we added four trials to the 37 trials included in the first published review version. Thirty trials were published over 20 years ago. Only one trial used adequate methods of randomization and allocation concealment, was blinded, and analysed all randomized participants. Only one trial used an E histolytica stool antigen test, and two trials used amoebic culture.Tinidazole may be more effective than metronidazole for reducing clinical failure (RR 0.28, 95% CI 0.15 to 0.51; 477 participants, eight trials; low-certainty evidence) and is probably associated with fewer adverse events (RR 0.65, 95% CI 0.46 to 0.92; 477 participants, 8 trials; moderate-certainty evidence). Compared with metronidazole, combination therapy may result in fewer parasitological failures (RR 0.36, 95% CI 0.15 to 0.86; 720 participants, 3 trials; low-certainty evidence), but we are uncertain which combination is more effective than another. Evidence is insufficient to allow conclusions regarding the efficacy of other antiamoebic drugs. AUTHORS' CONCLUSIONS Compared with metronidazole, tinidazole may be more effective in reducing clinical failure and may be associated with fewer adverse events. Combination drug therapy may be more effective for reducing parasitological failure compared with metronidazole alone. However, these results are based mostly on small trials conducted over 20 years ago with a variety of poorly defined outcomes. Tests that detect E histolytica more accurately are needed, particularly in countries where concomitant infection with other bacteria and parasites is common.
Collapse
Affiliation(s)
- Maria Liza M Gonzales
- University of the Philippines Manila College of Medicine‐Philippine General HospitalDepartment of PediatricsTaft AvenueManilaNational Capital RegionPhilippines1000
| | - Leonila F Dans
- University of the Philippines Manila College of Medicine‐Philippine General HospitalDepartment of PediatricsTaft AvenueManilaNational Capital RegionPhilippines1000
| | - Juliet Sio‐Aguilar
- University of the Philippines Manila College of Medicine‐Philippine General HospitalDepartment of PediatricsTaft AvenueManilaNational Capital RegionPhilippines1000
| | | |
Collapse
|
6
|
Mori M, Tsuge S, Fukasawa W, Jeelani G, Nakada-Tsukui K, Nonaka K, Matsumoto A, Ōmura S, Nozaki T, Shiomi K. Discovery of Antiamebic Compounds That Inhibit Cysteine Synthase From the Enteric Parasitic Protist Entamoeba histolytica by Screening of Microbial Secondary Metabolites. Front Cell Infect Microbiol 2018; 8:409. [PMID: 30568921 PMCID: PMC6290340 DOI: 10.3389/fcimb.2018.00409] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2018] [Accepted: 11/01/2018] [Indexed: 01/21/2023] Open
Abstract
Amebiasis is caused by infection with the protozoan parasite Entamoeba histolytica. Although metronidazole has been a drug of choice against amebiasis for decades, it shows side effects and low efficacy against asymptomatic cyst carriers. In addition, metronidazole resistance has been documented for bacteria and protozoa that share its targets, anaerobic energy metabolism. Therefore, drugs with new mode of action or targets are urgently needed. L-cysteine is the major thiol and an essential amino acid for proliferation and anti-oxidative defense of E. histolytica trophozoites. E. histolytica possesses the de novo L-cysteine biosynthetic pathway, consisting of two reactions catalyzed by serine acetyltransferase and cysteine synthase (CS, O-acetylserine sulfhydrylase). As the pathway is missing in humans, it is considered to be a rational drug target against amebiasis. In this study, we established a protocol to screen both a library of structurally known compounds and microbial culture extracts to discover compounds that target de novo cysteine biosynthesis of E. histolytica. The new screening system allowed us to identify the compounds that differentially affect the growth of the trophozoites in the cysteine-deprived medium compared to the cysteine-containing medium. A total of 431 structurally defined compounds of the Kitasato Natural Products Library and 6,900 microbial culture broth extracts were screened on the system described above. Five compounds, aspochalasin B, chaetoglobosin A, prochaetoglobosin III, cerulenin, and deoxyfrenolicin, from the Kitasato Natural Products Library, showed differential antiamebic activities in the cysteine-deprived medium when compared to the growth in the cysteine-containing medium. The selectivity of three cytochalasans apparently depends on their structural instability. Eleven microbial extracts showed selective antiamebic activities, and one fungal secondary metabolite, pencolide, was isolated. Pencolide showed cysteine deprivation-dependent antiamebic activity (7.6 times lower IC50 in the absence of cysteine than that in the presence of cysteine), although the IC50 value in the cysteine-deprived medium was rather high (283 μM). Pencolide also showed inhibitory activity against both CS1 and CS3 isoenzymes with comparable IC50 values (233 and 217 μM, respectively). These results indicated that antiamebic activity of pencolide is attributable to inhibition of CS. Cytotoxicity of pencolide was 6.7 times weaker against mammalian MRC-5 cell line than E. histotytica. Pencolide has the maleimide structure, which is easily attacked by Michael donors including the thiol moiety of cysteine. The cysteine-adducts of pencolide were detected by mass spectrometric analysis as predicted. As CS inhibition by the pencolide adducts was weak and their IC50 values to CS was comparable to that to the parasite in the cysteine-containing medium, the cysteine-adducts of pencolide likely contribute to toxicity of pencolide to the parasite in the cysteine-rich conditions. However, we cannot exclude a possibility that pencolide inactivates a variety of targets other than CSs in the absence of cysteine. Taken together, pencolide is the first compound that inhibits CS and amebic cell growth in a cysteine-dependent manner with relatively low mammalian cytotoxicity.
Collapse
Affiliation(s)
- Mihoko Mori
- Graduate School of Infection Control Sciences, Kitasato University, Tokyo, Japan
- Kitasato Institute for Life Sciences, Kitasato University, Tokyo, Japan
| | - Satoshi Tsuge
- Graduate School of Infection Control Sciences, Kitasato University, Tokyo, Japan
| | - Wataru Fukasawa
- Graduate School of Infection Control Sciences, Kitasato University, Tokyo, Japan
| | - Ghulam Jeelani
- Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Kumiko Nakada-Tsukui
- Department of Parasitology, National Institute of Infectious Diseases, Tokyo, Japan
| | - Kenichi Nonaka
- Graduate School of Infection Control Sciences, Kitasato University, Tokyo, Japan
- Kitasato Institute for Life Sciences, Kitasato University, Tokyo, Japan
| | - Atsuko Matsumoto
- Graduate School of Infection Control Sciences, Kitasato University, Tokyo, Japan
- Kitasato Institute for Life Sciences, Kitasato University, Tokyo, Japan
| | - Satoshi Ōmura
- Kitasato Institute for Life Sciences, Kitasato University, Tokyo, Japan
| | - Tomoyoshi Nozaki
- Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Kazuro Shiomi
- Graduate School of Infection Control Sciences, Kitasato University, Tokyo, Japan
- Kitasato Institute for Life Sciences, Kitasato University, Tokyo, Japan
| |
Collapse
|
7
|
Ohnishi K, Ainoda Y, Imamura A, Iwabuchi S, Okuda M, Nakano T. JAID/JSC Guidelines for Infection Treatment 2015-Intestinal infections. J Infect Chemother 2017; 24:1-17. [PMID: 28986191 DOI: 10.1016/j.jiac.2017.09.002] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2016] [Revised: 09/04/2017] [Accepted: 09/05/2017] [Indexed: 01/10/2023]
Affiliation(s)
| | | | | | - Kenji Ohnishi
- Tokyo Metropolitan Health and Medical Corporation Ebara Hospital, Tokyo, Japan
| | - Yusuke Ainoda
- Tokyo Metropolitan Health and Medical Corporation Ebara Hospital, Tokyo, Japan; Department of Infectious Diseases, Tokyo Women's Medical University, Japan
| | - Akifumi Imamura
- Department of Infectious Diseases, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan
| | - Sentaro Iwabuchi
- Department of Infectious Diseases, Tokyo Metropolitan Bokutoh General Hospital, Tokyo, Japan
| | - Masumi Okuda
- Department of Pediatrics, Sasayama Medical Center, Hyogo College of Medicine, Sasayama, Hyogo, Japan
| | - Takashi Nakano
- Department of Pediatrics, Kawasaki Medical School, Okayama, Japan
| |
Collapse
|
8
|
Hutcherson JA, Sinclair KM, Belvin BR, Gui Q, Hoffman PS, Lewis JP. Amixicile, a novel strategy for targeting oral anaerobic pathogens. Sci Rep 2017; 7:10474. [PMID: 28874750 PMCID: PMC5585216 DOI: 10.1038/s41598-017-09616-0] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2016] [Accepted: 07/24/2017] [Indexed: 01/27/2023] Open
Abstract
The oral microflora is composed of both health-promoting as well as disease-initiating bacteria. Many of the disease-initiating bacteria are anaerobic and include organisms such as Porphyromonas gingivalis, Prevotella intermedia, Fusobacterium nucleatum, and Tannerella forsythia. Here we investigated a novel therapeutic, amixicile, that targets pyruvate:ferredoxin oxidoreductase (PFOR), a major metabolic enzyme involved in energy generation through oxidative decarboxylation of pyruvate. PFOR is present in these anaerobic pathogenic bacteria and thus we hypothesized that amixicile would effectively inhibit their growth. In general, PFOR is present in all obligate anaerobic bacteria, while oral commensal aerobes, including aerotolerant ones, such as Streptococcus gordonii, use pyruvate dehydrogenase to decarboxylate pyruvate. Accordingly, we observed that growth of the PFOR-containing anaerobic periodontal pathogens, grown in both monospecies as well as multispecies broth cultures was inhibited in a dose-dependent manner while that of S. gordonii was unaffected. Furthermore, we also show that amixicile is effective against these pathogens grown as monospecies and multispecies biofilms. Finally, amixicile is the first selective therapeutic agent active against bacteria internalized by host cells. Together, the results show that amixicile is an effective inhibitor of oral anaerobic bacteria and as such, is a good candidate for treatment of periodontal diseases.
Collapse
Affiliation(s)
- Justin A Hutcherson
- Philips Institute of Oral Health Research, Virginia Commonwealth University, Richmond, Virginia, USA
| | - Kathryn M Sinclair
- Philips Institute of Oral Health Research, Virginia Commonwealth University, Richmond, Virginia, USA
- Department of Microbiology and Immunology, Virginia Commonwealth University, Richmond, Virginia, USA
| | - Benjamin R Belvin
- Philips Institute of Oral Health Research, Virginia Commonwealth University, Richmond, Virginia, USA
- Department of Biochemistry, Virginia Commonwealth University, Richmond, Virginia, USA
| | - Qin Gui
- Philips Institute of Oral Health Research, Virginia Commonwealth University, Richmond, Virginia, USA
| | - Paul S Hoffman
- Department of Medicine, Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, Virginia, USA
| | - Janina P Lewis
- Philips Institute of Oral Health Research, Virginia Commonwealth University, Richmond, Virginia, USA.
- Department of Microbiology and Immunology, Virginia Commonwealth University, Richmond, Virginia, USA.
- Department of Biochemistry, Virginia Commonwealth University, Richmond, Virginia, USA.
| |
Collapse
|
9
|
Bouraoui R, Limaiem R, Bouladi M, Mghaieth F, El Matri L. Effets secondaires neuro-ophtalmologiques du traitement par métronidazole chez l’enfant : à propos de deux cas. Arch Pediatr 2016; 23:167-70. [DOI: 10.1016/j.arcped.2015.11.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2015] [Revised: 07/07/2015] [Accepted: 11/08/2015] [Indexed: 10/22/2022]
|
10
|
Mori M, Jeelani G, Masuda Y, Sakai K, Tsukui K, Waluyo D, Tarwadi, Watanabe Y, Nonaka K, Matsumoto A, Ōmura S, Nozaki T, Shiomi K. Identification of natural inhibitors of Entamoeba histolytica cysteine synthase from microbial secondary metabolites. Front Microbiol 2015; 6:962. [PMID: 26441896 PMCID: PMC4568418 DOI: 10.3389/fmicb.2015.00962] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2015] [Accepted: 08/31/2015] [Indexed: 11/13/2022] Open
Abstract
Amebiasis is a common worldwide diarrheal disease, caused by the protozoan parasite, Entamoeba histolytica. Metronidazole has been a drug of choice against amebiasis for decades despite its known side effects and low efficacy against asymptomatic cyst carriers. E. histolytica is also capable of surviving sub-therapeutic levels of metronidazole in vitro. Novel drugs with different mode of action are therefore urgently needed. The sulfur assimilatory de novo L-cysteine biosynthetic pathway is essential for various cellular activities, including the proliferation and anti-oxidative defense of E. histolytica. Since the pathway, consisting of two reactions catalyzed by serine acetyltransferase (SAT) and cysteine synthase (CS, O-acetylserine sulfhydrylase), does not exist in humans, it is a rational drug target against amebiasis. To discover inhibitors against the CS of E. histolytica (EhCS), the compounds of Kitasato Natural Products Library were screened against two recombinant CS isozymes: EhCS1 and EhCS3. Nine compounds inhibited EhCS1 and EhCS3 with IC50 values of 0.31-490 μM. Of those, seven compounds share a naphthoquinone moiety, indicating the structural importance of the moiety for binding to the active site of EhCS1 and EhCS3. We further screened >9,000 microbial broths for CS inhibition and purified two compounds, xanthofulvin and exophillic acid from fungal broths. Xanthofulvin inhibited EhCS1 and EhCS3. Exophillic acid showed high selectivity against EhCS1, but exhibited no inhibition against EhCS3. In vitro anti-amebic activity of the 11 EhCS inhibitors was also examined. Deacetylkinamycin C and nanaomycin A showed more potent amebicidal activity with IC50 values of 18 and 0.8 μM, respectively, in the cysteine deprived conditions. The differential sensitivity of trophozoites against deacetylkinamycin C in the presence or absence of L-cysteine in the medium and the IC50 values against EhCS suggest the amebicidal effect of deacetylkinamycin C is due to CS inhibition.
Collapse
Affiliation(s)
- Mihoko Mori
- Kitasato Institute for Life Sciences, Kitasato UniversityTokyo, Japan
- Graduate School of Infection Control Sciences, Kitasato UniversityTokyo, Japan
| | - Ghulam Jeelani
- Department of Parasitology, National Institute of Infectious DiseasesTokyo, Japan
| | - Yui Masuda
- Graduate School of Infection Control Sciences, Kitasato UniversityTokyo, Japan
| | - Kazunari Sakai
- Graduate School of Infection Control Sciences, Kitasato UniversityTokyo, Japan
| | - Kumiko Tsukui
- Department of Parasitology, National Institute of Infectious DiseasesTokyo, Japan
| | - Danang Waluyo
- Biotech Center, Badan Pengkajian Dan Penerapan TeknologiBanten, Indonesia
| | - Tarwadi
- Biotech Center, Badan Pengkajian Dan Penerapan TeknologiBanten, Indonesia
| | - Yoshio Watanabe
- Research and Development Division, MicroBiopharm Japan Co. LtdIwata, Japan
| | - Kenichi Nonaka
- Kitasato Institute for Life Sciences, Kitasato UniversityTokyo, Japan
- Graduate School of Infection Control Sciences, Kitasato UniversityTokyo, Japan
| | - Atsuko Matsumoto
- Kitasato Institute for Life Sciences, Kitasato UniversityTokyo, Japan
- Graduate School of Infection Control Sciences, Kitasato UniversityTokyo, Japan
| | - Satoshi Ōmura
- Kitasato Institute for Life Sciences, Kitasato UniversityTokyo, Japan
| | - Tomoyoshi Nozaki
- Department of Parasitology, National Institute of Infectious DiseasesTokyo, Japan
- Graduate School of Life and Environmental Sciences, University of TsukubaTsukuba, Japan
| | - Kazuro Shiomi
- Kitasato Institute for Life Sciences, Kitasato UniversityTokyo, Japan
- Graduate School of Infection Control Sciences, Kitasato UniversityTokyo, Japan
| |
Collapse
|